Therefore, a more holistic evaluation of atrial pathology, ranging from EKG findings such as P terminal force in lead V1 (PTFV1), to echocardiographic parameters such as atrial size, and biomarkers such as NT-proBNP may allow for a more thorough assessment of embolic stroke risk than AF alone (196). This evidence concerns the gene NPPB and stroke disorder.